Status:
UNKNOWN
Tumor Growth Rate (TGR) Predicts Clinical Outcomes for Advanced Non-small Cell Lung Cancer Undergoing Immunotherapy.
Lead Sponsor:
Sun Yat-sen University
Collaborating Sponsors:
Guangdong Provincial Hospital of Traditional Chinese Medicine
Shanghai Chest Hospital
Conditions:
Non-Small Cell Lung Cancer
Eligibility:
All Genders
18+ years
Brief Summary
We hypothesized that TGR could serve as an early predictor of outcomes for aNSCLC patients undergoing immune checkpoint inhibitors (ICIs). A retrospective analysis was conducted to investigate the ass...
Detailed Description
Tumor growth rate (TGR) signifies percentage change in tumor size per month (%/m). Electronic medical records were retrospectively reviewed for all histologically confirmed aNSCLC patients undergoing ...
Eligibility Criteria
Inclusion
- Histologically confirmed aNSCLC patients
- Having received anti-PD-1/PD-L1 therapy
- Must have two consecutive computed tomography (CT) scans upon early treatment (from baseline to the first imaging evaluation)
Exclusion
- Lacking available computed tomography (CT) evaluation at any of two time points-baseline and the first evaluation
- Without measurable lesions at baseline CT scan
- Having received local anticancer therapy during ICI treatment, for example, radiotherapy and radiofrequency ablation
Key Trial Info
Start Date :
August 15 2019
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
August 1 2021
Estimated Enrollment :
350 Patients enrolled
Trial Details
Trial ID
NCT04722406
Start Date
August 15 2019
End Date
August 1 2021
Last Update
March 17 2021
Active Locations (3)
Enter a location and click search to find clinical trials sorted by distance.
1
Sun Yat-sen University Cancer Center
Guangzhou, Guangdong, China, 510060
2
Guangdong Provincial Hospital of Traditional Chinese Medicine
Guangzhou, Guangdong, China, 510120
3
Shaihai Chest Hospital
Shanghai, Shanghai Municipality, China, 200030